

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Prostate cancer	Xp11.22; 2p15	A genome-wide association study in about 10,000 prostate cancer patients from Iceland, The Netherlands, Spain, Sweden and the U.S. identified two SNPs that may predict susceptibility to disease: rs5945572 at Xp11.22 ( $p=3.95 \times 10^{-13}$ ) and rs721048 at 2p15 ( $p=7.66 \times 10^{-9}$ ). The latter variant was associated with more aggressive forms of prostate cancer. Further research is necessary to determine the biological link between these variants and prostate cancer. deCODE genetics Inc. has included the two markers in its PrCa prostate cancer DNA test.	Patent applications have been filed covering both diagnostic and therapeutic use of the genetic markers; available for licensing	Gudmundsson, J. <i>et al. Nat. Genet.</i> ; published online Feb. 10, 2008; doi:10.1038/ng.89 <b>Contact:</b> Julius Gudmundsson, deCODE genetics Inc., Reykjavik, Iceland e-mail: <a href="mailto:julius@decode.is">julius@decode.is</a>